Onconova Therapeutics
Onconova says Baxalta ends $565 million drug development deal for rigosertib
March 8, 2016Manufacturing and Production, Research and Development Baxalta, Onconova Therapeutics, drug development, rigosertib
Onconova Therapeutics says Baxalta has terminated its $565 million agreement to jointly develop the company’s lead drug candidate rigosertib. Baxalta …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
